AGR Summary
Chelsea Therapeutics International Ltd.
(NASD:CHTP)
Conservative
(89)
| Industry: | Pharmaceuticals - Diversified | Period End: | Mar 31, 2010 (Fiscal 2010 Q-1) | Statement Filing: | May 4, 2010 (10-Q) |
|---|---|---|---|---|---|
| Market Cap: | USD 163.2mm (Micro Cap) | Last Audit: | Ernst & Young LLP | Rating Published: | Jun 18, 2010 |
OVERVIEW
Chelsea Therapeutics International Ltd.
is currently rated as having
Conservative Accounting & Governance Risk (AGR).
This places them in the 89th
percentile among all companies, indicating higher accounting and governance risk than
11% of companies.
RISK SUMMARY
The forensic risk summary highlights material risks, if any, and lists the most material red flagged metric for each risk. AGR Impact shows the relative weight of the various red flagged metrics by risk type.
| Risk | AGR Impact | Top Flagged Metric |
|---|---|---|
| Corporate Governance Events | 0.0% | |
| High Risk Events | 0.0% | |
| Revenue Recognition | 0.0% | |
| Expense Recognition | 48.7% | Selling G&A Expenses/Operating Expense |
| Asset-Liability Valuation | 51.3% | Leverage Ratio: Debt/Equity |